Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Liping DouBo PengXin LiLu WangMingyu JiaLingmin XuFei LiDaihong LiuPublished in: Trials (2022)
ClinicalTrials.gov NCT04061876 (version number: 2019.5.18). Registered on July 16, 2019.